fashion -WSS

fashion

author：comprehensive 2025-09-28 18:47:38 - browse：9367

A collage illustration with a patient in the center with a hand to the left administering treatment and a doctor in the background. -- health tech coverage from STAT — Katy Lemay for STAT

The makers of minimally invasive surgical devices seemed poised to capture a wide swath of the obesity treatment market. Patients needed an option that lay between the two treatment extremes: cutting open the abdomen to perform permanent bariatric surgery, or changing your diet or exercise routine.

Then, a new class of weight loss medications that successfully mimic the feeling of fullness hit the market, and the landscape changed.

“It turns out that what came along — before those endoscopic devices have really matured — is these new drugs,” said Lee Kaplan, director of Massachusetts General’s obesity institute. Since the Food and Drug Administration approved Novo Nordisk’s Wegovy in 2021, it and similar drugs that followed have swiftly captured the public’s interest — and are on their way to generating billions of dollars in sales.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： FDA panel gives mixed vote on blood pressure devices

WSS

Supreme Court wrestles with OxyContin maker's bankruptcy deal

2024 GOP presidential candidates spar over abortion in debate

Radiation, mainstay of cancer treatment, begins a fade

Pfizer plans to depart BIO

Pfizer plans to depart BIO

AstraZeneca bets AAV gene therapy will still deliver the goods

focus

fashion

explore

How one medical school became remarkably diverse

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Heart attack and stroke risk calculators need revising

Apellis safety probe of eye disease drug centers on injection needle

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Patients' immediate access to test results puts radiologists in a bind

As demand for Covid shots wanes, Moderna seeks its next success

Drug firms test therapies to halt Alzheimer’s before symptoms arise

DIEP, the 'gold standard' of breast reconstruction, is under threat

Supreme Court wrestles with OxyContin maker's bankruptcy deal

hotspot

NYU Langone launches private ChatGPT for its health care data

FDA needs staff influx to meet gene therapy needs, Marks says

How to make Best Hospitals ratings actually useful for patients

Complete sequence of Y chromosome published for first time

AI models in health care face new federal disclosure requirements

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

leisure time

hotspot

focus

explore